Evidence map›Paper›PMID 27072050›Full record

Trial reportBritish journal of haematology2016

A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma.

Kohmei Kubo, Yasuhiko Miyazaki, Tohru Murayama, Ryutaro Shimazaki, Noriko Usui, Akio Urabe, Tomomitsu Hotta, Kazuo Tamura

Open access · hybridAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Observational
  7. Article
  8. Neutrophil diversity and function in health and disease.Signal transduction and targeted therapy · 2024
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Effects of filgrastim versus pegfilgrastim on outcomes of DA-R-EPOCH for non-Hodgkin's lymphoma.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 1 country.

Kohmei KuboDepartment of Haematology, Aomori Prefectural Central Hospital, Aomori, Japan.
Yasuhiko MiyazakiDepartment of Haematology, Oita Prefectural Hospital, Oita, Japan.
Tohru MurayamaDepartment of Haematology, Hyogo Cancer Centre, Hyogo, Japan.
Ryutaro ShimazakiR&D Division, Kyowa Hakko Kirin Co. Ltd, Tokyo, Japan.
Noriko UsuiDepartment of Clinical Oncology and Haematology, The Jikei University Daisan Hospital, Tokyo, Japan.
Akio UrabeNTT Medical Centre Tokyo, Tokyo, Japan.
Tomomitsu HottaNational Cancer Centre, Tokyo, Japan.
Kazuo TamuraDivision of Medical Oncology, Haematology and Infectious Disease, Fukuoka University, Fukuoka, Japan.
Aomori Prefectural Central Hospital · JPFukuoka University Hospital · JPHyogo Prefectural Cancer Center · JPKyowa Kirin (Japan) · JPNational Cancer Centre Japan · JPNTT Medical Center · JPOita Prefectural Hospital · JPThe Jikei University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pegfilgrastim is a pegylated form of the granulocyte-colony stimulating factor, filgrastim. Herein, we report the results of a multicentre, randomized, double-blind phase III trial comparing the efficacy and safety of pegfilgrastim with filgrastim in patients with malignant lymphoma. Patients were randomized to receive either a single subcutaneous dose of pegfilgrastim or daily subcutaneous doses of filgrastim on day 4 after the completion of cyclophosphamide, cytarabine, etoposide and dexamethasone ± rituximab (CHASE(R); day 1-3) chemotherapy. The primary endpoint was the duration of severe neutropenia (DSN), defined as the number of days with neutrophil count <0·5 × 10(9) /l in the first cycle of chemotherapy. A total of 111 lymphoma patients were randomized to either the pegfilgrastim or filgrastim group. 109 patients received either pegfilgrastim (n = 54) or filgrastim (n = 55). Efficacy data were available for 107 patients (pegfilgrastim: n = 53, filgrastim: n = 54). Both groups were well balanced in terms of gender, age, performance status and other variables. The mean DSN (±S.D.) was 4·5 (±1·2) and 4·7 (±1·3) d in the pegfilgrastim and filgrastim groups. No significant difference in safety was observed. This trial verified the non-inferiority of a single subcutaneous dose of pegfilgrastim compared with daily subcutaneous doses of filgrastim, considering DSN as an indicator.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideCytarabineDexamethasoneDisease ManagementDouble-Blind MethodEtoposideFemaleFilgrastimGranulocyte Colony-Stimulating FactorHumansLymphomaMaleMiddle AgedCyclophosphamideCytarabineDexamethasoneEtoposideFilgrastimGranulocyte Colony-Stimulating FactorpegfilgrastimPolyethylene GlycolsRecombinant ProteinsRituximabCHASE(R) chemotherapyfebrile neutropeniaG-CSFmalignant lymphomapegfilgrastim

Identifiers

PMID27072050
PMCPMC5074273
OpenAlexW2337734501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.